Sivik Global Healthcare LLC Buys 85,000 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Sivik Global Healthcare LLC lifted its position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 23.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 450,000 shares of the company’s stock after purchasing an additional 85,000 shares during the period. Sivik Global Healthcare LLC owned about 0.18% of Maravai LifeSciences worth $3,222,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Point72 Europe London LLP bought a new position in Maravai LifeSciences during the 4th quarter valued at approximately $17,059,000. 12 West Capital Management LP raised its holdings in shares of Maravai LifeSciences by 13.8% during the first quarter. 12 West Capital Management LP now owns 13,202,988 shares of the company’s stock valued at $114,470,000 after acquiring an additional 1,600,000 shares in the last quarter. Braidwell LP lifted its stake in Maravai LifeSciences by 26.8% in the fourth quarter. Braidwell LP now owns 5,040,635 shares of the company’s stock worth $33,016,000 after acquiring an additional 1,065,778 shares during the period. Bamco Inc. NY boosted its holdings in Maravai LifeSciences by 43.1% in the first quarter. Bamco Inc. NY now owns 2,123,651 shares of the company’s stock valued at $18,412,000 after acquiring an additional 640,000 shares in the last quarter. Finally, Principal Financial Group Inc. increased its position in Maravai LifeSciences by 3,349.6% during the 1st quarter. Principal Financial Group Inc. now owns 410,197 shares of the company’s stock valued at $3,556,000 after purchasing an additional 398,306 shares during the period. 50.25% of the stock is owned by hedge funds and other institutional investors.

Maravai LifeSciences Stock Down 1.7 %

Shares of NASDAQ:MRVI traded down $0.16 on Friday, hitting $9.05. 1,143,319 shares of the company traded hands, compared to its average volume of 2,416,354. The company has a market cap of $2.28 billion, a PE ratio of -9.14 and a beta of 0.02. The stock has a 50 day simple moving average of $8.41 and a 200-day simple moving average of $8.29. Maravai LifeSciences Holdings, Inc. has a 52 week low of $4.52 and a 52 week high of $11.56. The company has a quick ratio of 10.47, a current ratio of 11.32 and a debt-to-equity ratio of 0.71.

Maravai LifeSciences (NASDAQ:MRVI) last issued its earnings results on Wednesday, August 7th. The company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $73.40 million during the quarter, compared to analysts’ expectations of $71.64 million. Maravai LifeSciences had a negative return on equity of 4.28% and a negative net margin of 47.81%. The firm’s quarterly revenue was up 6.5% on a year-over-year basis. During the same period last year, the firm posted ($0.06) earnings per share. As a group, research analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on MRVI shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $15.00 target price on shares of Maravai LifeSciences in a research report on Friday, August 16th. UBS Group lifted their price objective on Maravai LifeSciences from $8.50 to $11.00 and gave the company a “neutral” rating in a research report on Thursday, August 8th. The Goldman Sachs Group increased their target price on Maravai LifeSciences from $7.00 to $8.00 and gave the stock a “neutral” rating in a research report on Thursday, August 8th. Morgan Stanley lowered Maravai LifeSciences from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $11.00 to $10.00 in a research report on Tuesday, August 13th. Finally, Robert W. Baird upped their price target on Maravai LifeSciences from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Thursday, May 9th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $10.78.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.